Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
PLUS THERAPEUTICS, Inc. (PSTV)
Company Research
Source: GlobeNewswire
HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX. Poster Spotlight Presentation:TitleRhenium (186Re) obisbemeda (rhenium nanoliposome, 186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results PresenterAndrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, Science Center at San Antonio PresentationDate/Time Friday, December 12, 2025, 7:39am to 7:42 am CST SessionDate/TimeFriday, December 12, 2025, 7:00am to 8:3
Show less
Read more
Impact Snapshot
Event Time:
PSTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSTV alerts
High impacting PLUS THERAPEUTICS, Inc. news events
Weekly update
A roundup of the hottest topics
PSTV
News
- Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual MeetingGlobeNewswire
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal MetastasesGlobeNewswire
- Plus Therapeutics (NASDAQ:PSTV) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
PSTV
Earnings
- 8/14/25 - Beat
PSTV
Sec Filings
- 11/17/25 - Form 8-K
- 11/5/25 - Form 4
- 10/30/25 - Form 10-Q
- PSTV's page on the SEC website